Point: Low-density lipoprotein cholesterol goals in patients with diabetes are not adequately based on evidence

被引：0
作者：
Gosmanov, Aidar R. [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Med, Div Endocrinol Metab Lipids, Atlanta, GA 30303 USA
来源：
JOURNAL OF CLINICAL LIPIDOLOGY | 2010年 / 4卷 / 01期
关键词：
RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; ARM ASCOT-LLA; HYPERTENSIVE PATIENTS; ATORVASTATIN; PREVENTION; OUTCOMES; DISEASE; PRAVASTATIN; CORONARY;
D O I：
10.1016/j.jacl.2009.12.003
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：69 / 71
页数：3
相关论文
共 10 条
  • [1] [Anonymous], 2002, JAMA, V288, P2998
  • [2] [Anonymous], DIABETES CARE S1
  • [3] Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation
    Brunzell, John D.
    Davidson, Michael
    Furberg, Curt D.
    Goldberg, Ronald B.
    Howard, Barbara V.
    Stein, James H.
    Witztum, Joseph L.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (15) : 1512 - 1524
  • [4] Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
    Colhoun, HM
    Betteridge, DJ
    Durrington, PN
    Hitman, GA
    Neil, HAW
    Livingstone, SJ
    Thomason, MJ
    Mackness, MI
    Charlton-Menys, V
    Fuller, JH
    [J]. LANCET, 2004, 364 (9435) : 685 - 696
  • [5] Collins R, 2003, LANCET, V361, P2005
  • [6] Efficacy and safe of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes - The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)
    Knopp, Robert H.
    D'Emden, Michael
    Smilde, Johan G.
    Pocock, Stuart J.
    [J]. DIABETES CARE, 2006, 29 (07) : 1478 - 1485
  • [7] Current overview of statin-induced myopathy
    Rosenson, RS
    [J]. AMERICAN JOURNAL OF MEDICINE, 2004, 116 (06) : 408 - 416
  • [8] Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes:: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA)
    Sever, PS
    Poulter, NR
    Dahlöf, B
    Wedel, H
    Collins, R
    Beevers, G
    Caulfield, M
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Ostergren, J
    [J]. DIABETES CARE, 2005, 28 (05) : 1151 - 1157
  • [9] Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
    Sever, PS
    Dahlöf, B
    Poulter, NR
    Wedel, H
    Beevers, G
    Caulfield, M
    Collins, R
    Kjeldsen, SE
    Kristinsson, A
    McInnes, GT
    Mehlsen, J
    Nieminen, M
    O'Brien, E
    Östergren, J
    [J]. LANCET, 2003, 361 (9364) : 1149 - 1158
  • [10] Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
    Shepherd, J
    Blauw, GJ
    Murphy, MB
    Bollen, ELEM
    Buckley, BM
    Cobbe, SM
    Ford, I
    Gaw, A
    Hyland, M
    Jukema, JW
    Kamper, AM
    Macfarlane, PW
    Meinders, AE
    Norrie, J
    Packard, CJ
    Perry, IJ
    Stott, DJ
    Sweeney, BJ
    Twomey, C
    Westendorp, RGJ
    [J]. LANCET, 2002, 360 (9346) : 1623 - 1630
1